This website uses cookies to enhance the user experience.
CONCEPTOMED AS

CONCEPTOMED AS998 089 433

Research
Limited company
Hattvikveien 2 8373 BALLSTAD, Norge

CONCEPTOMED AS

SalivaPOD™ - Saliva collection of DNA/RNA for PCR - ConceptoMed
Maximize flexibility and adaptability for Test-and-Trace operations. Utilize existing PCR diagnostic systems with highest sensitivity

Keywords

researchdevelopment worknatural sciencesengineeringtechnologymedicineagricultureinterdisciplinary research

Links

Organization

Chairman of the board
Years since formation
12 years
since Mar 14, 2012
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
110,440
1 share class
Total number of shareholders
3
companies
Belongs to group of

Financials

Total operating income 2023
446,581
NOK
Annual total result 2023
-4,592,640
NOK
Total equity 2023
9,643,957
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO
13.35 %
indirectly

Board

NameRoleShares
Chairman
6.92 %
indirectly
Board Member
13.35 %
indirectly
Observer-

Others

NameRoleShares
K
KPMG AS
Auditor-
Accountant-

Top 10 individual shareholders

NameRoleShares
Managing Director/CEO, Board Member
13.35 %
indirectly
-
8.63 %
indirectly
-
8.63 %
indirectly
Chairman
6.92 %
indirectly
AL
-
6.92 %
indirectly
-
6.65 %
indirectly
Last update: Aug 28, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
G
GOOD KARMA INVEST AS
Ordinary shares
63,559
57.55 %
B
BRAVE CAPITAL AS
Ordinary shares
24,793
22.45 %
X
XINVESTOR AS
Ordinary shares
22,088
20 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 0
    Operating profit 2023: NOK -11,543
    Employees: 0

Financials

in NOK

Summary

Year202320222021
Total operating income
446,581
0
14,122,320
Annual Total Result
-4,592,640
-5,535,761
7,051,026
Total assets
20,691,948
21,806,998
26,039,148
Total liabilities
11,047,991
7,570,401
6,266,789
Total equity
9,643,957
14,236,597
19,772,359

P&L

Year202320222021
Total operating income
446,581
0
14,122,320
Total operating costs
5,021,969
5,441,201
7,066,236
Operating result
-4,575,388
-5,441,201
7,056,084
Financial income/costs
-17,252
-94,561
-5,058
Profit before tax
-4,592,640
-5,535,761
7,051,026
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
-4,592,640
-5,535,761
7,051,026

Balance overview

Year202320222021
Total fixed assets
15,904,830
15,878,000
13,939,000
Total current assets
4,787,118
5,928,998
12,100,148
Total assets
20,691,948
21,806,998
26,039,148
Short term debt
10,715,294
7,358,143
6,140,904
Long term debt
332,697
212,258
125,885
Total liabilities
11,047,991
7,570,401
6,266,789
Contributed capital
9,643,957
12,721,333
12,721,333
Retained earnings
0
1,515,265
7,051,026
Total equity
9,643,957
14,236,597
19,772,359
Total equity and liabilities
20,691,948
21,806,998
26,039,148

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.19
Industrial group
Other research and experimental development on natural sciences and engineering
72.190
Industrial group
Other research and experimental development on natural sciences and engineering